2nd Jul 2010 10:53
Epistem Holdings Plc ("Epistem" or the "Company")
Directors' Shareholdings
Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009.
As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors have each increased their beneficial interest in the Company by 282 ordinary shares of 1.5p each. These shares were acquired in tranches at the end of April, May and June 2010 at prices of 417p, 415p and 363p respectively.
The current beneficial interests of the executive Directors are set out below:
Matthew Walls 7,183 (0.09%)
Dr Catherine Booth 981,538 (12.37%)
Dr Ged Brady 1,538 (0.02%)
Dr Jeffrey Moore 16,038 (0.20%)
John Rylands 191,436 (2.41%)
For further details please contact:
Epistem Plc
Matthew Walls, CEO +44 161 606 7258
KBC Peel Hunt Ltd.
James Steel / Vijay Barathan +44 20 7418 8900
Related Shares:
Genedrive